RB1 and large cell neuroendocrine carcinoma: A particularly high frequency of TP53/RB1 co‐alteration was observed in respiratory system tumors (964/8835 cases, 10.91%), with the highest frequency observed in SCLC (475/657 cases, 72.30%), followed by LCNEC (36/121 cases, 29.75%), lung squamous cell carcinoma (LUSC) (123/1411 cases, 8.72%), and LUAD (327/6312 cases, 5.18%).